Indeed, TNBC is characterized by the absence of estrogen and progesterone receptors (ER/PR) and absence of human epidermal growth factor receptor 2 (HER2) overexpression, making it unresponsive to the conventional therapies used for the other BC subtypes. The gene discussed is PGR; the disease is breast cancer.